Top Injectable Manufacturer in Tunisia – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 8 min read
Last Updated: August 23, 2026
TL;DR: Tunisia regulates medicines through ANMPS (Agence Nationale des Médicaments et des Produits de Santé), the more autonomous authority created in 2023 to take over the historic role of the Direction de la Pharmacie et du Médicament (DPM), with registration running on the CTD format and moving toward mandatory eCTD submission from 2026. Despite a genuine domestic manufacturing base led by companies such as UNIMED and SIPHAT, Tunisia still imports the bulk of its active pharmaceutical ingredients and many complex, biologic, and specialty sterile injectables, and has lived through real, documented medicine-shortage episodes tied to import-financing pressure. Rising diabetes and cardiovascular disease, alongside steady maternal-health needs, keep demand for dependable injectables high. Tunisia's 2018 accession to the Hague Apostille Convention simplifies certificate legalization, though a locally licensed representative remains mandatory. Farbe Firma, a WHO-GMP certified sterile injectable manufacturer in Gujarat, India, producing 100+ injectable products under ISO Class 5 aseptic conditions and exporting to 30+ countries, supports Tunisian importers with CTD/ACTD-ready dossiers built for this landscape.
Key Takeaways
Tunisia's medicines are regulated by the Agence Nationale des Médicaments et des Produits de Santé (ANMPS), created under Law n° 2023-2 of July 2023 to modernize oversight once carried out by the Direction de la Pharmacie et du Médicament (DPM). Dossiers follow the CTD format, filed in French or English with certain sections in French and/or Arabic, and Tunisia's 2025 registration guide steers the market toward mandatory eCTD submission through 2026. Marketing authorization is issued as an Authorization for Market Commercialization (AMC), and Farbe Firma structures its CTD/ACTD packages to match ANMPS's current requirements.
Unlike many countries in this series, Tunisia has genuine domestic injectable manufacturing capacity, led by companies such as UNIMED alongside SIPHAT and Opalia Pharma, and local products are heavily weighted in public-sector tenders. However, Tunisia's active pharmaceutical ingredients remain overwhelmingly imported, complex, biologic, and specialty sterile injectables stay import-dependent, and the country has documented real shortage episodes since 2022 tied to currency and import-financing pressure. We could not confirm a current, published WHO Global Benchmarking Tool maturity level for Tunisia and have not stated one here.
Tunisia acceded to the Hague Apostille Convention in 2017 (in force since March 2018), so Certificates of Pharmaceutical Product and GMP certificates from India, an Apostille member since 2005, can generally move through the faster apostille route rather than full consular legalization. Foreign manufacturers must still appoint a locally licensed representative or importer recognized by ANMPS/DPM to file and hold the dossier, and Pharmacie Centrale de Tunisie (PCT) retains an import monopoly on the medicines within its remit for the public sector.
Tunisia's disease burden is shifting firmly toward noncommunicable disease: the IDF Diabetes Atlas records diabetes in roughly 10.8% of Tunisian adults, and WHO EMRO reporting attributes more than 30% of all deaths in the country to cardiovascular disease. A relatively low maternal mortality ratio of 36 per 100,000 live births (2023) still depends on reliable access to injectable oxytocics, anesthetics, and antibiotics. Radès and Sfax ports plus Tunis-Carthage's cold-chain air cargo capacity give Farbe Firma workable, if not instantaneous, routes to market.
Introduction: Why an Injectable Manufacturer in Tunisia Must Meet Global Standards
Tunisia occupies an unusual position in North Africa's pharmaceutical landscape. It is one of the few countries in this series with an established domestic drug industry, yet it still relies on international suppliers for a meaningful share of its sterile injectable medicines, particularly active pharmaceutical ingredients, biologics, and specialty formulations that local plants are not yet equipped to produce at scale. Any injectable manufacturer in Tunisia looking to supply hospitals, clinics, and pharmacies here has to clear the same bar Tunisian regulators set for domestic producers: consistent sterility assurance, validated analytical testing, and documentation that satisfies the Agence Nationale des Médicaments et des Produits de Santé (ANMPS), the agency created in 2023 to modernize oversight once carried out by the Direction de la Pharmacie et du Médicament (DPM).
Farbe Firma Pvt Ltd, based in Gujarat, India, has built its export business around exactly that bar. As a WHO-GMP certified sterile injectable manufacturer, the company operates ISO Class 5 aseptic filling lines that produce more than 100 injectable products, from small-volume parenterals to specialty formulations, and ships to more than 30 countries under CTD and ACTD dossier formats. For Tunisian importers and institutional buyers evaluating an injectable manufacturer in Tunisia's supply chain, that combination of certified quality systems and dossier-readiness is what shortens the distance between a supplier shortlist and a signed registration file.
What Sets a World-Class Injectable Manufacturer in Tunisia Apart
Tunisia's regulatory environment has changed meaningfully in the past few years. ANMPS, established by Law n° 2023-2 of 12 July 2023, now runs registration, pharmacovigilance, and national drug-control laboratory functions that once sat inside the DPM, and it launched a redesigned digital portal in early 2025 alongside an updated Human Medicines Registration Guide in June 2025. Dossiers still follow the CTD format, filed in French or English with select sections in French and/or Arabic, but Tunisia's roadmap moves the market toward mandatory e-submission from May 2026 and exclusive eCTD filing from June 2026. Marketing authorization is granted as an Authorization for Market Commercialization (AMC), and because every foreign manufacturer must work through a locally licensed representative, that partner's regulatory-affairs capability often matters as much as the dossier itself.
We have not found a current, publicly confirmed WHO Global Benchmarking Tool maturity classification for Tunisia's regulator, so we won't guess at one here; what is verifiable is that Tunisia is actively investing in the kind of digitized, traceable regulatory infrastructure the GBT framework rewards. It's also worth being direct about something this series doesn't always address: Tunisia already manufactures a substantial share of its own medicines, including sterile products, through established local players. What Tunisia has not yet built out at scale is domestic capacity for complex, biologic, and specialty sterile injectables, which is why the country remains a meaningful import destination in exactly the categories Farbe Firma manufactures, even as it prioritizes local generic producers in public tenders.
Quality Systems Behind Every Batch We Ship to Tunisia
Every batch bound for Tunisia moves through the same analytical panel we apply everywhere: HPLC and GC methods confirm identity, assay, and related-substance profiles against USP, BP, IP, or EP monographs, Karl Fischer titration verifies water content in moisture-sensitive formulations, and sterility testing plus LAL (bacterial endotoxin) assays confirm each lot is free of viable microorganisms and pyrogens. Particulate matter counts, pH, osmolality, and fill-volume checks round out release testing, because a sterile injectable manufacturer in Tunisia's supply chain has no margin for a batch that passes on paper but fails on the bench.
Stability data is generated under ICH Q1A(R2) long-term and accelerated conditions, with photostability assessed per ICH Q1B, so shelf-life claims hold up under Tunisia's Mediterranean climate and the realities of onward distribution once cargo clears customs. From Gujarat, shipments typically move by air into Tunis-Carthage International Airport, which offers cold-chain-capable cargo handling, or by sea into the Port of Radès, Tunisia's principal container gateway, with the Port of Sfax serving as an alternative for bulk shipments. None of that removes the need to plan around customs clearance timelines and inland cold-chain handling to the final pharmacy or hospital shelf.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Tunisia for Global Buyers
Farbe Firma's injectable portfolio lines up closely with what Tunisia's disease burden actually demands. The IDF Diabetes Atlas puts diabetes prevalence at roughly 10.8% of Tunisian adults, close to 870,000 people, and WHO's regional office reports that cardiovascular disease alone accounts for more than 30% of all deaths nationally, with noncommunicable diseases linked to the large majority of mortality. That translates into sustained demand for insulin and other antidiabetic injectables, cardiovascular emergency and critical-care injectables, and antibiotics for infections that complicate chronic disease management. Tunisia's maternal mortality ratio, 36 per 100,000 live births in 2023 per UN interagency estimates, is comparatively favorable for the region, but sustaining it depends on reliable access to injectable oxytocics, anesthetics, and antibiotics in delivery rooms and operating theatres.
Beyond finished-dose supply, Farbe Firma works with Tunisian importers and regional distributors as a CDMO and private-label partner, developing formulations and packaging suited to local branding and tender specifications. Our standard registration package includes the Certificate of Pharmaceutical Product in WHO format, our WHO-GMP certificate, and full CTD documentation; since India and Tunisia are both Hague Apostille Convention members, these certificates typically move through apostille rather than the slower embassy-legalization chain. That matters for buyers supplying Pharmacie Centrale de Tunisie (PCT), the public sector's central purchasing body, whose tenders cover a substantial share of total market value and lean heavily on price and documentation completeness, as well as for programs supported by financing such as the World Bank's 2025 health-system-strengthening loan to Tunisia.
In practice, what decides a Tunisia launch timeline is rarely the manufacturing side. It's how quickly a compliant CTD dossier can be assembled, how experienced the local representative is at navigating ANMPS's transition to mandatory eCTD submission, and how realistically a buyer plans shipping lead time between Gujarat and Tunisian ports or Tunis-Carthage's air cargo terminal. We tell prospective partners the same thing regardless of country: build in time for dossier queries, plan logistics around actual customs and cold-chain handling rather than best-case transit days, and treat the local agent relationship as a long-term partnership, not a one-time formality. Given Tunisia's documented history of import-financing-linked shortages, buyers who plan conservatively on logistics and payment terms tend to fare better than those who assume a smooth first shipment.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer for Tunisia?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer based in Gujarat, India, operating ISO Class 5 aseptic filling lines and producing more than 100 injectable products for export to over 30 countries. Our dossiers are prepared in CTD and ACTD formats to match what Tunisia's ANMPS (and, before it, the DPM) requires for registration, and we can supply the Certificate of Pharmaceutical Product and GMP certificate that Tunisian importers need to open a marketing-authorization file.
How does injectable product registration actually work in Tunisia?
A locally licensed representative submits a CTD-format dossier to ANMPS (Agence Nationale des Médicaments et des Produits de Santé), the agency created in 2023 that took over the registration role once run by the DPM. The dossier is filed in French or English, with certain sections in French and/or Arabic, and Tunisia is moving toward mandatory eCTD submission through 2026. Once reviewed, the product receives an Authorization for Market Commercialization (AMC); timelines vary with dossier quality, so we recommend budgeting conservatively rather than assuming a fast-track review.
Do we need a local partner or agent to sell injectables in Tunisia?
Yes. Tunisian rules require foreign manufacturers to work through a locally licensed representative or authorized importer who files and holds the registration dossier. For products destined for the public sector, Pharmacie Centrale de Tunisie (PCT) also holds import-monopoly and central-purchasing authority over the medicines in its remit, so many institutional sales route through PCT tenders. Farbe Firma can work alongside your chosen Tunisian representative to prepare and maintain the technical file.
Which injectables are in strongest demand in Tunisia?
Given Tunisia's rising noncommunicable disease burden, insulin and other antidiabetic injectables, cardiovascular and critical-care injectables, and broad-spectrum injectable antibiotics see consistent institutional demand, alongside maternal-health injectables such as oxytocics and obstetric anesthetics. Tunisia also imports complex, biologic, and specialty sterile injectables that its domestic manufacturers do not yet produce at scale, which is where an experienced export-focused manufacturer like Farbe Firma is most useful to Tunisian buyers.
What documentation and logistics considerations matter most for a Tunisia launch?
On documentation, plan around a CTD dossier (moving to mandatory eCTD in 2026), a Certificate of Pharmaceutical Product, a WHO-GMP certificate, and apostille rather than consular legalization, since India and Tunisia both belong to the Hague Apostille Convention. On logistics, shipments from Gujarat typically move by air into Tunis-Carthage's cold-chain cargo terminal or by sea into the Port of Radès, with Sfax as an alternative; given Tunisia's documented history of import-financing-related shortages, build buffer time into customs clearance and payment-cycle planning.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments